INDIANAPOLIS — Eli Lilly and Co. plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis facilities.
Eli Lilly said the investment will be used to replace a current insulin vial-filling line. The move also stands to enable the company to meet rising demand for its insulins — including Humalog (insulin lispro) and Humulin (human insulin) — while upgrading to state-of-the-art technology and readying for its insulin pipeline.
“This new project is part of $850 million in anticipated U.S. capital investments which Lilly announced in March of this year. It reinforces our ongoing commitment to the U.S. market and in Indianapolis specifically,” chairman and chief executive officer David Ricks stated. “Our company is poised for continued growth, and diabetes represents one of our key therapeutic areas. Investments such as this are vital to ensuring we continue meeting the needs of people who use our medicines.”
Insulin is a pillar of Eli Lilly’s diabetes business, and in turn its U.S. manufacturing operations are a linchpin of insulin supply, the company noted. The company said the Indianapolis insulin manufacturing facility plays a key role, and replacing the existing line will allow for the installation of a new insulin vial filling line that aligns with modern design expectations and uses updated technology.
“As technology and science continually advance, it is important that our manufacturing facilities are recapitalized and modernized regularly to ensure we can continue to provide a reliable supply of safe and high-quality medicines to people around the world,” commented Maria Crowe, president of Lilly global manufacturing operations.
Lilly added that it has invested more than $1.2 billion since 2012 to bolster its U.S. diabetes product manufacturing operations.